Addiction Medicine Practice Software

Addiction medicine practices provide medication-assisted treatment and comprehensive care for substance use disorders. Patients require intensive monitoring during early recovery with frequency decreasing as stability increases. The between-visit period is clinically critical — cravings, triggers, and relapse risk are constant. Traditional practice has limited visibility into this period.

Medication-assisted treatment for opioid use disorder using buprenorphine, methadone, or naltrexone requires ongoing adherence monitoring. Patients who stop MAT medications face high relapse risk. Diversion concerns require careful tracking. RTM through the clinIQ app provides visibility into medication adherence and recovery status between visits.

Regulatory requirements create documentation burden. DEA requirements for controlled substance prescribing, state regulations for MAT programs, PDMP checks, urine drug screen protocols, and treatment agreement maintenance all require tracking. Patient flow and analytics can document that compliance steps occur without replacing the mandated systems themselves.

Patient engagement is both challenging and essential. Patients in early recovery face daily struggles with cravings, triggers, and life circumstances that threaten recovery. Between-visit support through secure messaging and symptom tracking through the patient app extends the therapeutic relationship beyond periodic visits.

Co-occurring psychiatric conditions are common. Depression, anxiety, PTSD, and other mental health conditions frequently accompany substance use disorders. Coordination with psychiatry and behavioral health providers ensures comprehensive treatment. Pain management coordination addresses the complex intersection of chronic pain and opioid use disorder.

RTM billing captures revenue for between-visit monitoring that addiction medicine inherently requires. CPT 98976 for behavioral health device supply plus 98980 and 98981 for treatment management time apply to substance use disorder monitoring.

Qualifying monitoring includes craving intensity and frequency tracking, trigger identification and avoidance, medication adherence for MAT, mood and psychiatric symptom tracking for co-occurring conditions, sleep quality relevant to recovery, and recovery milestone tracking. This monitoring is clinically essential and now billable through RTM.

Patient-reported data collection through the clinIQ app captures daily or weekly check-ins on craving levels, substance use episodes if any, medication adherence logging, trigger encounters and coping responses, mood ratings for co-occurring depression or anxiety, and recovery support activity like meeting attendance.

The revenue opportunity shows $110-140 per enrolled patient monthly combining device supply and treatment management codes. One hundred patients enrolled generates $11,000-14,000 monthly or $130,000-168,000 annually. Addiction medicine patients in active treatment are candidates throughout their care episodes.

Compliance rates in addiction treatment can be challenging, but the clinIQ app design addresses engagement barriers. Simple interfaces require minimal effort. Push notifications maintain connection. The clinical relationship reinforces tracking importance. Achievement recognition for recovery milestones motivates continued engagement.

Clinical value from RTM data includes early identification of relapse risk through craving escalation, verification of medication adherence between visits, trigger pattern recognition informing behavioral interventions, and mood tracking revealing co-occurring psychiatric exacerbation. Secure messaging enables outreach when concerning patterns emerge rather than waiting for the next scheduled visit.

Medication-assisted treatment adherence directly determines treatment success. Patients who stop taking buprenorphine, naltrexone, or other MAT medications face significantly elevated relapse risk. Monitoring adherence between visits through the clinIQ app enables intervention before relapse occurs.

Buprenorphine adherence tracking captures when patients take their prescribed sublingual or injection doses. Daily medication logging creates a record visible to the prescriber. Patterns of missed doses trigger concern and outreach. Adherence data visible before visits informs clinical discussion.

Naltrexone monitoring for both oral and injectable forms tracks adherence and response. For oral naltrexone, daily logging verifies consistent use. For Vivitrol injections, appointment adherence and response tracking between injections maintains clinical visibility.

Adherence reminders through push notifications help patients remember medication doses at scheduled times. The reminder links to medication logging, making it easy to confirm the dose was taken. For patients whose adherence challenge is forgetting, reminders solve the problem directly.

Non-adherence intervention through secure messaging addresses problems before they escalate. When adherence data shows missed doses, clinical staff can reach out to understand barriers. Is it side effects? Loss of medication? Ambivalence about treatment? Early intervention prevents full treatment discontinuation.

Diversion monitoring uses adherence patterns alongside clinical judgment. Patients claiming to take medication whose adherence logging is inconsistent may warrant closer attention. Drug screen results compared with reported adherence patterns reveal discrepancies requiring investigation.

Analytics track adherence rates across the patient population, identifying patients at risk and supporting quality improvement. Aggregate adherence data demonstrates program effectiveness to regulatory bodies and payers.

Recovery from substance use disorder involves ongoing management of cravings, triggers, and life circumstances that threaten sobriety. Tracking these factors through the clinIQ app provides clinical insight and supports patient self-awareness.

Craving tracking captures intensity and frequency of substance cravings. Patients rate craving intensity daily or when cravings occur. The data reveals patterns invisible without systematic tracking. A patient whose cravings escalate on certain days or in certain contexts gains insight that supports behavioral change.

Trigger identification through tracking reveals what circumstances precede craving spikes. Stress at work, conflict in relationships, certain locations, or emotional states may trigger cravings. Pattern recognition from RTM data informs trigger avoidance and coping strategies discussed in treatment.

Recovery support tracking documents engagement with recovery activities. Meeting attendance, sponsor contact, sober support connection, and recovery-oriented activities all support sustained recovery. Tracking creates accountability and identifies when support engagement declines.

Relapse prevention through early warning detection uses RTM data patterns. Escalating cravings, declining mood, reduced recovery support engagement, and medication adherence drops may precede relapse. When these patterns emerge, secure messaging or telehealth outreach can intervene before relapse occurs.

Recovery milestone celebration reinforces progress. Days in recovery, treatment completion markers, and personal achievements tracked through the app create positive feedback. Patients who see their progress documented feel encouraged to continue.

Wearable integration adds physiological data relevant to recovery. Sleep quality from Apple Watch or Oura Ring correlates with mood and craving intensity. Activity levels indicate engagement versus withdrawal. Heart rate variability may reflect stress levels that increase relapse risk.

Addiction medicine operates under extensive regulatory oversight. DEA requirements for controlled substance prescribing, state regulations for MAT programs, and payer requirements all demand documentation that patient flow and analytics support.

PDMP verification must occur before controlled substance prescriptions according to state requirements. The patient flow workflow documents that PDMP checks occurred with timestamps, though actual verification happens in the state portal. This creates audit trail satisfying regulatory inquiry.

Urine drug screen tracking captures when screens are ordered, collected, resulted, and reviewed. The workflow ensures screens happen on schedule based on treatment phase and clinical need. Missing or overdue screens surface in workflow alerts. Results discrepant with reported use trigger clinical attention.

Treatment agreement tracking documents patient acknowledgment of treatment expectations, responsibilities, and consequences. Agreement status showing signed, current, expired, or needs renewal appears in patient workflow. Agreements requiring renewal surface before visits.

Prescription monitoring documents controlled substance prescriptions with quantities, dates, and refill patterns. This documentation supports both clinical review and regulatory compliance demonstration.

Analytics generate compliance reports showing PDMP check completion rates, drug screen frequency and results, treatment agreement currency, and prescribing patterns. These reports support internal quality assurance and external audit response.

Inspection readiness means documentation exists and is retrievable. When DEA or state regulators inspect the practice, compliance documentation from patient flow timestamps and analytics demonstrates systematic compliance rather than relying on staff attestation.

Addiction medicine works best as part of comprehensive care addressing co-occurring conditions and supporting whole-person recovery. Coordination with other providers enhances outcomes.

Behavioral health therapy coordination supports the psychological dimensions of recovery. Cognitive behavioral therapy, motivational interviewing, and other therapeutic approaches address the thoughts, emotions, and behaviors underlying addiction. Secure messaging enables communication between prescribers and therapists. Shared RTM data visibility means both providers see consistent patient information about mood, cravings, and recovery activities.

Psychiatry coordination addresses co-occurring psychiatric conditions common in addiction. Depression, anxiety, PTSD, and bipolar disorder frequently accompany substance use disorders. The addiction medicine provider and psychiatrist must align on medication management. Shared RTM data and secure messaging facilitate coordination.

Primary care coordination addresses medical complications of substance use and general health needs. Hepatitis screening, HIV testing, cardiac assessment, and routine preventive care all matter for addiction medicine patients. Secure file exchange shares relevant documentation with PCPs maintaining the medical home relationship.

Pain management coordination addresses the complex intersection of chronic pain and opioid use disorder. Patients with both conditions require careful coordination to manage pain without undermining recovery. Secure messaging enables direct communication between addiction medicine and pain management providers.

Community resource connection supports recovery beyond clinical treatment. Sober living facilities, employment services, and recovery community organizations all contribute to sustained recovery. The patient app can provide resource information and track engagement with community supports.

Telehealth expanded dramatically for addiction medicine during the pandemic with regulatory flexibilities that have largely been maintained. Video visits through the clinIQ app provide access for patients facing barriers to in-person care.

Buprenorphine prescribing via telehealth remains permitted under current DEA guidance with appropriate clinical protocols. Patients can receive initial evaluations and ongoing medication management through telehealth when clinically appropriate. This access is particularly valuable in rural areas with limited addiction medicine providers.

Patient access barriers that telehealth addresses include transportation challenges significant for patients without reliable vehicles, geographic distance from treatment facilities, childcare or work schedule conflicts, and stigma concerns about being seen entering treatment facilities. Telehealth removes these barriers while maintaining clinical relationship.

RTM data review during telehealth visits enables data-informed discussion. The provider sees craving patterns, medication adherence, and recovery activity while talking with the patient. Video visits supported by between-visit monitoring data can be more productive than in-person visits without such data.

Scheduling through the patient app shows both telehealth and in-person options. Appointment reminders include appropriate join instructions. The unified platform means patients use the same app for visits, messaging, and recovery tracking.

Group therapy via telehealth extends peer support access. Group sessions for patients in similar recovery phases can meet virtually, maintaining connection when in-person attendance is difficult.

Hybrid models combining in-person and telehealth visits based on treatment phase and patient needs optimize both access and clinical care. Early treatment may benefit from more in-person contact while stable patients may prefer telehealth convenience.

Addiction medicine implementation focuses on RTM enrollment, medication adherence tracking, compliance documentation, and telehealth integration.

Week one maps clinical workflows including intake processes, visit frequency patterns, compliance documentation, and coordination with other providers. Scheduling templates configure for initial evaluations and follow-ups at varying frequencies. RTM data collection configures for cravings, adherence, mood, and recovery tracking. Compliance tracking workflows configure for PDMP, drug screens, and treatment agreements.

Week two trains clinical staff on patient flow workflows including compliance documentation, RTM data review, and telehealth operation. Administrative staff trains on scheduling and check-in. Staff practices enrolling patients in RTM through the patient app.

Week three goes live with RTM enrollment beginning, compliance tracking active, and telehealth available. The clinIQ team monitors implementation and adjusts configuration.

ROI sources include RTM billing revenue at $110-140 per enrolled patient monthly with 100 patients generating $130,000+ annually. Telehealth expands patient reach without facility expansion. Compliance documentation reduces regulatory risk. Better monitoring may improve outcomes and reduce costly relapse events.

Professional tier at $499 monthly includes RTM, telehealth, patient flow, scheduling, secure messaging, wearable integration, and analytics. RTM revenue from 50 enrolled patients exceeds annual platform cost.